Market Overview

Vertex, GlaxoSmithKline Enter Agreement for Phase 2 Hepatitis C Study

Related VRTX
The Daily Biotech Pulse: Vertex Awaits FDA Verdict, Strongbridge Falls On Offering, ReShape's Woes Continue
The Week Ahead: Nvidia, Retailer Earnings In Focus
FDA OKs expanded use for Vertex Pharma's Kalydeco (Seeking Alpha)

Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced it has
entered into a non-exclusive agreement with GlaxoSmithKline (NYSE: GSK) to
conduct a Phase 2 proof-of-concept study of an all-oral regimen for the
treatment of hepatitis C containing Vertex's nucleotide analogue
hepatitis C virus (HCV) polymerase inhibitor VX-135 and GSK's NS5A
inhibitor GSK2336805. Vertex and GSK plan to initiate the study in early
2013, pending discussions with regulatory authorities. The study is
expected to evaluate safety, tolerability and viral cure rates using a
12-week combination of VX-135 and GSK2336805. The companies will jointly
fund costs associated with the study. There are no up-front or milestone
payments associated with the agreement. VX-135 is an investigational
uridine nucleotide analogue pro-drug designed

See full press release

Posted-In: News Guidance Contracts Management Stock Split Global


Related Articles (VRTX + GSK)

View Comments and Join the Discussion!

UPDATE: Spectra Energy Q3 Profit Down 30%

Benzinga's Top Upgrades